Table 3.

The need for APLA testing and management with enough literature support

The need for APLA testing and management with enough literature support
Condition/group of conditions	APLA testing according to literature	Treatment
Solid tumors	Not routinely [43]
Infectious diseases	Not routinely [51]
Rheumatic and musculoskeletal diseases	Not routinely [78]
Solid and hematological malignancies	NO [40]
Covid-19	NO [54, 55]
pSS	YES-LA [81]
Asymptomatic APLA carriers—high risk profiles		Primary prophylaxis - low dose aspirin [1, 101]
APS (with documented thrombosis episodes)		Secondary prophylaxis: 1) VKA therapeutic INR target 2–3 or DOAC if contraindications (NOT rivaroxaban in triple APLA positive) [1] or 2) DOAC-single or double APLA positive patients [101] VKA-triple APLA positive patients [101]
APLA positive women/OAPS		1) LDA before conception - In high-risk profiles with no previous history of thromboembolism or obstetrical complications [1] 2) LMWH (+ LDA) if miscarriages previously [1, 97] VKA are contraindicated! The published data underline the positive influence of hydroxychloroquine or prednisone, which can be used safely and successfully during pregnancy [1, 104, 105].